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Original Article

Exosomal DNA Aptamer Targeting a-Synuclein
Aggregates Reduced Neuropathological
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The a-synuclein aggregates are the main component of Lewy
bodies in Parkinson’s disease (PD) brain, and they showed
immunotherapy could be employed to alleviate a-synuclein
aggregate pathology in PD. Recently we have generated DNA
aptamers that speciﬁcally recognize a-synuclein. In this study,
we further investigated the in vivo effect of these aptamers on
the neuropathological deﬁcits associated with PD. For efﬁcient
delivery of the aptamers into the mouse brain, we employed
modiﬁed exosomes with the neuron-speciﬁc rabies viral glycoprotein (RVG) peptide on the membrane surface. We demonstrated that the aptamers were efﬁciently packaged into the
RVG-exosomes and delivered into neurons in vitro and in vivo.
Functionally, the aptamer-loaded RVG-exosomes signiﬁcantly
reduced the a-synuclein preformed ﬁbril (PFF)-induced pathological aggregates, and rescued synaptic protein loss and
neuronal death. Moreover, intraperitoneal administration of
these exosomes into the mice with intra-striatally injected
a-synuclein PFF reduced the pathological a-synuclein aggregates and improved motor impairments. In conclusion, we
demonstrated that the aptamers targeting a-synuclein aggregates could be effectively delivered into the mouse brain by
the RVG-exosomes and reduce the neuropathological and
behavioral deﬁcits in the mouse PD model. This study highlights the therapeutic potential of the RVG-exosome delivery
of aptamer to alleviate the brain a-synuclein pathology.

INTRODUCTION
Parkinson’s disease (PD) is the most prevalent form of synucleinopathies, which include PD, PD dementia (PDD), multiple system atrophy (MSA), and dementia with Lewy bodies (DLB). It is characterized
by the abnormal deposition of the a-synuclein protein in the form of
aggregates in neurons, leading to cell death and subsequent behavioral and motor deﬁcits.1 Currently, none of the existing therapies
are able to slow down the neurodegeneration cascades that affect
the diseased brain.2 Therefore, to effectively delay or halt the progression of the disease, it is necessary to develop effective disease-modifying alternatives.
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The tendency of a-synuclein to form aggregates is the key for its pathological function. a-Synuclein is a primarily cytosolic intracellular
protein found at the presynaptic terminal,3 and it is believed to
have a role in vesicular transport and neurotransmitter release.4
The a-synuclein aggregates, once taken up by acceptor cells, can act
as seeds for further a-synuclein deposition within the recipient cells.
This mechanism can explain the neurodegeneration pattern observed
at different PD stages.5,6 Thus, the processes of a-synuclein aggregation and ﬁbrillation can be used as the therapeutic targets for the
treatment of PD.7
Immunotherapy has emerged as a promising approach to target and
clear the a-synuclein aggregate pathology in PD.5,8 Although several
agents have been identiﬁed to disrupt the a-synuclein aggregation,9–11 the antibody-based immunotherapy is more appealing.
The studies have shown that the antibodies against intracellular
a-synuclein can inhibit a-synuclein aggregation and restore neurodegeneration in the mouse models.12–14 Similarly, the immunotherapies
against the other disease-causing proteins, such as Ab,15 tau,16,17
SOD1,18 and Huntingtin,19 have been shown to decrease the protein
aggregation and neurodegeneration. However, the later clinical trials
of some antibodies, such as aducanumab, cannot reach their primary
endpoint. Due to the protein nature, antibodies have their own weaknesses. For example, the antibodies do not easily get access to the
intracellular target, and they are signiﬁcantly immunogenic and
more thermally unstable.20 Therefore, there is an urgent need to
develop antibody alternatives for application of the immunotherapy
in PD. Aptamers are short, single-stranded DNA (ssDNA) or RNA
molecules that can bind to a wide range of target proteins. They are
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usually considered as “chemical antibodies.” Aptamers have several
advantages when compared with antibodies. First, they are neither
immunogenic nor toxic molecules. Moreover, they have higher thermal stability and can maintain their structures over repeated cycles of
denaturation and renaturation. In addition, they can even discriminate between different conformations of the same target protein,21,22
although with some cross-interaction between the different forms of
intrinsically disordered proteins.23 Recently, we identiﬁed two DNA
aptamers that speciﬁcally recognize a-synuclein. These aptamers
can inhibit a-synuclein aggregation in a neuronal cell line and primary neurons, and reduce mitochondrial dysfunction and cell defects
induced by a-synuclein overexpression.24 Thus, it warrants further
in vivo investigation of these aptamers for their ability to inhibit the
a-synuclein aggregation and reduce neuropathological deﬁcits.
Developing a safe and efﬁcient vehicle to deliver an aptamer into the
brain is still a challenging task. For siRNA delivery, three types of the
delivery vehicle have been used, including viruses, polycationic polyethylenimine (PEI)-based nanoparticles, and liposomes.25–27 However, these approaches are limited by stereotactic surgery, immune
activation, toxicity problems, and non-speciﬁc targeting.28,29 Interestingly, Alvarez-Erviti et al.30 developed modiﬁed exosomes by fusing
the neuron-speciﬁc rabies viral glycoprotein (RVG) peptide to the extra-exosomal N terminus of Lamp2b, an abundant membrane protein
of the exosome, to allow the exosomes to enter the brain efﬁciently.
The intravenous injection of RVG-modiﬁed exosomes, loaded with
small interfering RNA (siRNA), into the normal mice leads to the targeted silencing of Beta-secretase130 or opioid receptor mu expression31 in the brain. Furthermore, Cooper et al.32 employed these
nano-sized vesicles to deliver the a-synuclein siRNA into the mouse
brain, and consequently reduced the intraneuronal a-synuclein aggregates and reversed the brain a-synuclein pathological condition,
further highlighting its potential therapeutic value for neurological
diseases.
In this study, we packaged the aptamers that recognized the a-synuclein ﬁbrillar aggregates into the RVG-modiﬁed exosomes and investigated whether these exosomes were able to clear a-synuclein
pathological aggregates in the cultured neurons and in vivo with the
a-synuclein PFF-inoculated wild-type (WT) mice. It showed that in
the primary neurons the RVG-exosomes loaded with aptamers significantly reduced the PFF-induced phosphorylated a-synuclein aggregates and rescued synaptic protein loss and neuron death. After
systemic administration of these exosomes into the a-synuclein PFFinoculated WT mice, the pathological a-synuclein aggregates in the
brain were signiﬁcantly reduced, and the associated motor dysfunction
was rescued. In short, our study provided a potential therapeutic alternative via RVG-exosomes loaded with aptamers for treatment of PD.

RESULTS
Characterization of the DNA Aptamers and Selection of Aptamer
for Therapy

Previous studies demonstrated that injection of the mouse a-synuclein preformed ﬁbrils (PFFs) into young WT mice resulted in pro-

gressively recruiting endogenous mouse a-synuclein to form
aggregates and further spreading of a-synuclein pathology.33 Thus,
targeting the a-synuclein aggregates appears to be a viable option
to halt the initial step of synucleinopathies. Here we asked whether
our previous selected aptamers could recognize the a-synuclein aggregates for PD treatment.
To characterize our selected aptamers, we ﬁrst prepared the a-synuclein ﬁbrillar aggregates in vitro. Speciﬁcally, the a-synuclein PFF was
prepared in PBS with constant agitation from the puriﬁed recombinant human and mouse a-synuclein proteins. After separating the
aggregated a-synuclein proteins from the soluble ones by ultracentrifugation, the majority of a-synuclein was present in the pellet (Figure 1A) in the form of high-molecular-weight aggregates as detected
by western blot (Figure S1A). The morphology of the a-synuclein aggregates was further conﬁrmed by transmission electron microscopy
(TEM) analysis. The results showed human and mouse a-synuclein
aggregates were large and broad with the ribbon-like ﬁbrils. In
contrast, the ﬁbril-like structures were not detected in the soluble
fraction of mouse a-synuclein (Figure 1B) or in the human a-synuclein monomer (data not shown). Taken together, the above data
collectively conﬁrmed that the human and mouse a-synuclein PFFs
were both well-made.
Next, to test the aptamer capability to recognize the ﬁbrillar a-synuclein, we performed the aptamer blotting along with the BSA control
(Figure 1C). The results showed that the aptamers of F5R1 and F5R2
both bound to the human monomeric a-synuclein protein, but not
BSA, as previously published.24 Interestingly, both F5R1 and F5R2
had high afﬁnities to human and mouse a-synuclein PFF. At the
same time, F5R1 also bound slightly with the mouse monomeric
a-synuclein protein. In contrast, F5R2 showed no binding signal to
these monomers. We further conﬁrmed the aptamer F5R2 did not
react with the mouse monomeric a-synuclein in different amounts
with serial dilutions (Figure S1B). Thus, for in vivo use, the aptamer
F5R2 will not interfere with the endogenous a-synuclein in mice.
Furthermore, we conﬁrmed that aptamer F5R2 exhibited no reactivity
with Ab42 oligomers and its ﬁbrils, although it bound slightly with
the lysozyme ﬁbrils (Figures S1C and S1D).
Because the interaction between a-synuclein PFF and a-synuclein
monomers could seed progressive monomer aggregation,34 we hypothesized that the binding of our aptamer to the a-synuclein PFF
would prevent its interaction with the monomer, and thus inhibit
the a-synuclein PFF-mediated progressive a-synuclein aggregation
process. To test this hypothesis, we used thioﬂavin T (ThT) binding
assay. Our result demonstrated that the presence of aptamer F5R2
signiﬁcantly attenuates the a-synuclein PFF seeding process in vitro
(Figure 1D). In the ThT binding assay for amyloid ﬁbrils, the extent
of ThT binding to amyloid ﬁbrils depends on the accessibility of binding grooves or “channels” formed in ﬁbril b sheets.35 For a-synuclein,
the presence of the aptamers, which could bind with the PFF, will
probably interfere with ThT interacting with a-synuclein ﬁbrils. In
this scenario, we further employed the electron microscopy to assess
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Figure 1. Characterization of the DNA Aptamers
(A) The a-synuclein PFF was prepared in PBS with constant agitation. After the a-synuclein fibril (pellet fraction) was separated from the a-synuclein monomer (supernatant
fraction) by ultracentrifuge, the proteins were resolved by 10% SDS-PAGE and stained with Coomassie blue. Lane 1, purified human a-synuclein alone; lanes 2–3, supernatant and pellet fraction after human a-synuclein protein agitation; lane 4, purified mouse a-synuclein alone; lanes 5–6, supernatant and pellet fraction after mouse
a-synuclein protein agitation. (B) TEM image of the a-synuclein PFF (pellet fraction) with the mouse monomeric a-synuclein (supernatant fraction) as a control. Scale bar,
200 nm. (C) Aptamer recognition capability assay by dot blotting. One-microgram samples (BSA, human monomeric a-synuclein, human a-synuclein PFF, mouse
monomeric a-synuclein, mouse a-synuclein PFF) were respectively immobilized onto the nitrocellulose membrane for binding of each aptamer. (D) Aptamers could inhibit
PFF-induced aggregation in vitro. Human a-synuclein monomer (20 mM) was incubated with 10% PFF in the presence of aptamer F5R2 (2 mM) at 37 C under shaking at
1,000 rpm. After shaking for 24 h, the amyloid formation was monitored by measuring ThT fluorescence. Values are presented as mean ± SD. One-way ANOVA followed by
Tukey’s post hoc test (n = 6 independent experiments for each group), **p < 0.01.

the effect of aptamer F5R2 on this process to exclude this possibility
(Figure S2).
Based on the aptamer recognition capability and its capacity to inhibit
a-synuclein PFF seeding efﬁciency, we chose the aptamer F5R2 for
the subsequent therapy in the mouse a-synuclein PFF model of the
sporadic PD because this aptamer could bind to the aggregated a-synuclein without interfering with the endogenous mouse a-synuclein,
potentially leading to the inhibition of a-synuclein aggregation in
the mice.
Characterization of RVG-Exosomes and Its Delivery of the
Aptamer into Neuronal Cells

To facilitate delivery of the aptamer into the mouse brain, we generated the neuron-speciﬁc exosomes according to the previous publication.30 The RVG-modiﬁed exosomes were characterized by TEM and
western blotting. The TEM data showed that the exosomes presented
normal morphological characteristics, with an average diameter of
approximately 100 nm, and that each vesicle was surrounded by a
double-layer membrane (Figure 2A); western blot analysis showed
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that the exosome marker protein Alix could be detected in a dosedependent manner with increasing sample loading (Figure S3D).
These characteristics indicated that the exosome properties were
not affected by the RVG modiﬁcation. Further immunoprecipitation
results suggested that RVG-positive exosomes account for around
18% of the total ones (Figure S3C).
Next, we investigated the loading of aptamers into RVG-modiﬁed
exosomes using the PEI transfection protocol. Alexa 594-labeled
aptamer was used for ﬂuorometric detection after transfection,
and the amount of encapsulated aptamers was assayed after ultracentrifugation. The ﬂuorescent plate reading data showed that
transfection for 2 h resulted in the greatest retention of aptamer
(Figure S4A). This was further conﬁrmed by confocal microscope,
showing that most of the exosomes were co-localized with aptamers
(Figure S4B). Furthermore, the PEI transfection did not substantially alter the physical properties of the RVG-exosomes loaded
with aptamers (Figure S3B). For the subsequent loading of aptamers
into exosomes, unless otherwise noted, transfection with PEI for 2 h
was used.
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Figure 2. Characterization of RVG-Exosomes and Their Delivery of Aptamer F5R2 into Neuronal Cells
(A) TEM image of the RVG-exosomes purified from the culture medium of HEK293T cells. Scale bar, 200 nm. (B) Confocal microscopy images, showing the delivery of
aptamers F5R2 into the neuronal cells by RVG-exosomes. Vehicle (columns 1 and 5), naked aptamer F5R2-Alexa 594 (columns 2 and 6), aptamer F5R2-Alexa 594-loaded
unmodified exosomes (columns 3 and 7), and aptamer F5R2-Alexa 594-loaded RVG-exosomes (columns 4 and 8). Scale bars, 25 mm. (C) Bar graph quantitation of the
fluorescence intensity of the packaged aptamers. For each group, the fluorescence intensity was measured with six independent chamber slides (three fields per slide were
counted). The aptamers packaged into the cells were expressed as fluorescence intensity and were normalized to the group of the unmodified exosomes + aptamer for
statistical comparisons. Values are presented as mean ± SD. One-way ANOVA followed by Tukey’s post hoc test, ****p < 0.0001. (D) Confocal microscopy images of
fluorescently labeled aptamer F5R2 in primary neurons. The MAP2 (green) was used as the marker of neurons. Scale bars, 25 mm.

To conﬁrm RVG-exosomes can deliver aptamers into neurons,
we selected the Neuro2A cell line as the recipient cells, with the
skeletal muscle cell C2C12 as the control. First, after conﬁrming
the exosomes could deliver the aptamers into the Neuro2A cells
at 24 h (Figure S4C), the confocal image showed that the ﬂuorescence intensity in the cells was increased with time, suggesting
that the aptamer uptake efﬁciency was positively correlated with
the incubation time. The incubation for 48 h resulted in the highest
exosome uptake efﬁciency (Figures S4D and S4E). Next, to conﬁrm
the RVG-exosome targeting capabilities, Neuro2A cells were treated
with the RVG-exosomes loaded with the aptamers for 48 h.
The result showed that these cells were ﬂuorescently detectable under ﬂuorescence confocal microscopy; however, the cells untreated
or treated with aptamer alone or WT-exosome alone had very
weak ﬂuorescent signals (Figure 2B). In contrast, RVG-exosomes
could not efﬁciently enter the non-neuronal C2C12 cells. This is
likely due to that the cell line does not have the RVG peptide recep-

tor on their membrane (Figures 2B and 2C). In addition, both cell
lines could tolerate the aptamer-loaded exosomes treatment, as
reﬂected by lactate dehydrogenase (LDH) assay and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay
(Figure S5).
To further conﬁrm the aptamer-delivery effect of RVG-exosomes in
the primary neurons, we treated the mouse primary neurons with
the RVG-exosomes loaded with Alexa 594-labeled aptamers for
24 h. The confocal scanning data showed that the aptamers could
be delivered into the primary neurons through the RVG-exosomes
(Figure 2D).
Taken together, these data clearly demonstrated that the RVG peptide
incorporation into the exosomal membrane preferentially guides the
exosomes to neuronal cells, allowing for efﬁcient delivery of the aptamer into the neuronal recipient cells.
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Figure 3. Aptamers Could Reduce PFF-Induced
Insoluble Pathologic Aggregates in Primary
Neurons
Primary neurons were treated with RVG-exosomes
loaded with the aptamer or random DNA sequence at 6
DIV and then treated with PBS or PFF at 7 DIV. (A) At 14
DIV, neurons were fixed with 4% PFA with or without 1%
TX-100 to extract soluble proteins. Confocal microscopy
was used to monitor endogenous mouse a-synuclein
(red) and p-a-synuclein (green) in neurons. Scale bars,
25 mm. (B) Neurons were lysed sequentially in 1% TX-100
(TX-soluble) followed by 2% SDS (TX-insoluble) at 21 DIV,
and western blotting was used to analyze the level of
mouse a-synuclein and p-a-synuclein in the lysates. Onetenth dose of aptamer-loaded RVG-exosomes was
applied as the low-dose treatment group, and similarly
the 1/10 random DNA sequence group was also set as
the negative control. The b-actin was served as the
loading control. (C) Bar graph quantitation of the protein
level of endogenous mouse a-synuclein from the TXinsoluble fraction. Values are presented as mean ± SD.
One-way ANOVA followed by Tukey’s post hoc test (n = 3
independent experiments for each treatment), *p < 0.05,
**p < 0.01 compared with the group treated with a
random DNA sequence. (D) Bar graph quantitation of the
protein level of p-a-synuclein from the TX-insoluble fraction. Values are presented as mean ± SD. One-way
ANOVA followed by Tukey’s post hoc test (n = 3 independent experiments for each treatment), *p < 0.05,
**p < 0.01 compared with the group treated with a
random DNA sequence.
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The Aptamers Reduced PFF-Induced Insoluble Pathologic
Aggregates in the Mouse Primary Neurons

After conﬁrming that aptamers could be efﬁciently delivered into
the neuronal cells through RVG-exosomes, we then assessed
whether aptamers packaged in the RVG-exosomes could inhibit
the a-synuclein aggregation and suppress pathological changes
caused by PFF in the primary neurons. To achieve this goal, we
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delivered aptamers to the mouse primary
neurons via the RVG-exosomes 24 h before
the human a-synuclein PFF treatment. On
the 7th day after PFF treatment, in the PBStreated group, endogenous mouse a-synuclein
diffusely distributed in cells. However, this
distribution pattern was signiﬁcantly disturbed
in the PFF-treated neurons because of the
recruitment of endogenous mouse a-synuclein
into aggregates (Figure 3A, upper panels; Figure S6). Then, we extracted neurons using
the ﬁxation buffer containing 1% Triton
X-100 (TX-100) to determine whether these
a-synuclein aggregates were insoluble. Under
this experimental condition, endogenous
mouse a-synuclein in the PBS group was
completely extracted, whereas the PFF-treated
group showed TX-100-insoluble aggregates. Interestingly, addition
of the RVG-exosomes loaded with the aptamer reduced the extent
of the ﬁbrillar aggregation. In contrast, random DNA sequence
had no effect on a-synuclein aggregation pattern (Figure 3A, upper
panels). Thus, the aptamer delivered into the primary neurons
inhibited the formation of the a-synuclein insoluble aggregates
induced by PFF.
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In addition, previous studies showed that phosphorylation of the
serine residue at the 129 position of a-synuclein (p-a-syn) is a marker
of intracellular a-synuclein pathology because exogenously added
PFF lacks this modiﬁcation.36 We further tried to conﬁrm the presence of pathological a-synuclein by measuring the phosphorylation
level of Ser129 of the a-synuclein protein. In the PBS-treated group,
we did not observe the presence of p-a-syn, whereas in the PFFtreated group, the presence of p-a-syn was clearly visible in the aggregated state. Furthermore, the p-a-syn-positive inclusions were still
remarkably detected even after TX-100 treatment, but not in the
PBS-treated group. Notably, this pathology was signiﬁcantly reduced
by the aptamer treatment, but not by a random DNA sequence treatment (Figure 3A, lower panels), suggesting aptamer could inhibit PFF
to recruit endogenous mouse a-synuclein into p-a-syn-positive inclusions. Thus, these results demonstrated that the aptamer delivered
into the primary neuron via RVG-exosomes reduced a-synuclein
Ser129 phosphorylation level caused by PFF.

Figure 4. Aptamers Reduced a-Synuclein PFFInduced Synaptic Loss and Neuron Death
(A) Primary neurons were similarly treated as in Figure 3.
At 21 DIV, proteins of SNAP25 and synapsin II in TXsoluble fraction were analyzed by western blot. b-Actin
was served as the loading control. (B and C) Bar graph
quantitation of the protein level of synapsin II (B) and
SNAP25 (C) from the TX-soluble fraction. Values are
presented as mean ± SD. One-way ANOVA followed by
Tukey’s post hoc test (n = 3 independent experiments for
each treatment), *p < 0.05. (D) Bar graph quantitation of
the LDH level in culture media at 21 DIV. Values are
presented as mean ± SD. One-way ANOVA followed by
Tukey’s post hoc test (n = 6 independent experiments for
each group), **p < 0.01.

to 69.74% ± 13.00% (Figures 3B and 3C). At the
same time, TX-insoluble p-a-synuclein fraction
was also signiﬁcantly reduced to 70.75% ±
4.43%, and one-tenth dose of the aptamer treatment reduced to 86.37% ± 1.72% (Figures 3B
and 3D). Collectively, these data further demonstrated that aptamers
could reduce PFF-induced insoluble pathologic aggregates.
Aptamers Rescued the Synaptic Protein Loss and Neuron Death
Induced by PFF

Previous studies demonstrated PFF-induced a-synuclein aggregates
might cause the synaptic protein loss and neuron death.36,37 Here,
we further tested whether the aptamers could reduce the synaptic protein loss and protect against the neuron death. Indeed, whereas PFF
treatment resulted in a loss of the synaptic protein of synapsin II
and SNAP25, addition of the aptamers clearly preserved their protein
level (Figures 4A–4C). Moreover, the aptamer treatment signiﬁcantly
reduced the LDH level caused by the PFF treatment. This effect was
not observed in the group treated with a random DNA sequence (Figure 4D). Therefore, the aptamer could prevent the synaptic protein
loss and potentially rescue the neuron death induced by PFF.
RVG-Exosomes Delivered Aptamers into the Mouse Brain

Furthermore, the above ﬁndings were bolstered by western blotting
analysis. The soluble and insoluble a-synuclein fractions were prepared after sequentially extracting neurons in 1% TX-100 followed
by 2% SDS. The western blotting results showed that TX-insoluble
a-synuclein was present in the group treated with PFF (Figure 3B),
suggesting that mouse endogenous a-synuclein was recruited into
Lewy body (LB) or Lewy neurite (LN)-like aggregates by PFF. Particularly, the higher-molecular-weight a-synuclein bands detected by
antibody to a-synuclein or p-a-syn in the TX-insoluble fractions of
PFF-treated cultures are also evident, likely corresponding to phosphorylated, multimeric, or other posttranslational modiﬁed forms of
a-synuclein (Figure 3B). Notably, those aggregates in TX-insoluble
preparation were dramatically reduced by aptamer treatment to
60.36% ± 6.37%, when compared with the group treated with a random
DNA sequence, and one-tenth dose of the aptamer treatment reduced

To determine whether aptamers could also reduce a-synuclein aggregation and its associated neuropathology in vivo, ﬁrst we need to
know whether the aptamers can be efﬁciently delivered into the brain
tissues by RVG-exosomes. For this purpose, the CellVue Claretlabeled RVG-exosomes loaded with Alexa 594-labeled aptamers
were intraperitoneally injected into the C57BL/6J mice (2–3 months
old) with aptamer alone as the control. Twenty-four hours later, the
mice were anesthetized, perfused, and the brain slides were scanned
by confocal microscopy. The images indicated that the purple
RVG-exosomes and red Alexa 594 were detectable in the brain cortex
and midbrain, and no ﬂuorescence was detected in the control group
(Figures 5A and 5B). This suggests that the aptamer was delivered
into the brain efﬁciently by the RVG-exosomes, but not by the
unmodiﬁed exosomes (Figures S7A and S7B). In addition, the immune responses analysis further indicated that the treatment with
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Figure 5. RVG-Exosomes Delivered Aptamers
Efficiently into the CNS in Mice
CellVue Claret-labeled RVG-exosomes loaded with Alexa
594-labeled aptamer F5R2 were administered into mice
by intraperitoneal injection. Mice were anesthetized and
sacrificed 24 h after the injection, and the brain was
sectioned at a thickness of 40 mm. (A) Confocal microscopy images show the delivery of aptamers F5R2 (red)
into the brain cortex by RVG-exosomes (purple). Scale
bars, 75 mm. (B) Sections were stained with antibodies
(anti-MAP2, anti-TH, anti-GFAP, and anti-Iba-1) to
localize the aptamers F5R2/RVG-exosomes with different
cells in the mouse midbrain.
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Figure 6. Aptamers Rescued the Mouse Grip Strength Loss Induced by PFF
(A) Schematic representation of experimental design. (B and C) Wire hang (B) and
rotarod task (C) performance of mice at 30 days post PFF injection with aptamerloaded RVG-exosomes treatment. RVG-exosomes group loaded with a random
DNA sequence was used as the control. Values are presented as mean ± SD. Oneway ANOVA followed by Tukey’s post hoc test (n = 12 mice per group), ***p < 0.001;
n.s., not significant, compared with RVG-exosomes group loaded with a random
DNA sequence. (D) The weights of mice were measured before and after aptamerloaded RVG-exosome treatment, to verify whether the treatment could be tolerated
by animals. Values are presented as mean ± SD. Two-way ANOVA followed by
Tukey’s post hoc test (n = 12 mice per group). There was no significant difference
between each group.

RVG-exosomes loaded with aptamers did not induce signiﬁcant immune responses in vivo (Table S1).
To identify the cell types in the brain with the delivered aptamers, we
co-stained the brain slides with different biomarkers. Confocal images
showed that the aptamer and RVG-exosomes were co-localized in the
neurons, microglia, and astrocytes in the midbrain (Figure 5B),
implying that the aptamer indeed was delivered into the brain cells
whose membrane contains the neuronal nicotinic acetylcholine receptors. Taken together, these results suggested that RVG-exosomes
could deliver aptamers into the mouse brain by intraperitoneal injection. This method was selected for the further evaluation of aptamer
therapeutic effects in vivo.
Aptamers Rescued the Mouse Grip Strength Loss Induced by
PFF and Reduced the Accumulation of the Pathological
a-Synuclein Aggregates In Vivo

After demonstrating that the aptamer could be delivered to the mouse
brain by RVG-exosomes and reduce pathological a-synuclein aggre-

gates in the primary neurons, we then asked whether aptamers could
reduce the a-synuclein pathology in vivo. To this end, we used the
mouse a-synuclein PFF model of the sporadic PD, and the RVG-exosomes loaded with the aptamer were intraperitoneally injected into
the C57BL/6J female mice (2–3 months old). Twenty-four hours later,
mouse a-synuclein PFF was injected into the right striatum of the
mice. During the next 4 weeks, the mice were given RVG-exosomes
loaded with aptamer weekly. The RVG-exosomes loaded with
random DNA sequence were given to the mice as the negative control
(Figure 6A). Thirty days after PFF injection, the efﬁcacy of the aptamer therapy was assessed with the behavioral and histological
analyses.
To assess the effect of aptamers on the motor function, we performed
the wire hang test and rotarod test. The wire hang test measures the
time until the animal loses its grip. The results demonstrated that
non-PFF-treated mice were holding on to the wire for 158 s on
average, whereas the PFF-treated mice were able to hold on only
around 54 s. Notably, the aptamer treatment signiﬁcantly enhanced
the time of the mice on the wire (around 150 s). In contrast, this effect
was not observed in the group treated with a random DNA sequence
(Figure 6B). For the rotarod task, the mice performance exhibited no
difference between the naive and PFF-treated group, so it was practically impossible to see the effect of aptamer on their rotarod performance at this time point (Figure 6C). In addition, the mice tolerated
the aptamer treatment well, because they gained weight normally and
appeared healthy until the termination of the experiment (Figure 6D).
Collectively, these data indicated that the aptamer could rescue the
grip strength loss induced by PFF.
Next, we determined whether aptamers could reduce the pathological
a-synuclein aggregates in the brain. In the control group treated with
a random DNA sequence, the aggregation of p-a-syn was primarily
detected in the ipsilateral cortex, although the p-a-syn signals were
also detected on the contralateral side. Noteworthy, in the aptamertreated group, the aggregation of p-a-syn in the ipsilateral and contralateral cortex was signiﬁcantly reduced (Figures 7A–7C). Moreover,
for the substantia nigra, in the group treated with a random DNA
sequence, the aggregation of p-a-syn was detected only in the ipsilateral substantia nigra, but not in the contralateral substantia nigra.
This observation is consistent with a previous report.37 Importantly,
the aptamer treatment signiﬁcantly depressed the aggregation of
p-a-syn in the ipsilateral substantia nigra (Figures 7D and 7E).
Thus, the administration of aptamers reduced the pathology in this
a-synuclein PFF mouse model of PD.
In addition, because the aptamers also could be delivered into the
brain microglia and astrocytes, the quantity and morphology of microglia and astrocyte cells were also assessed with glial ﬁbrillary acidic
protein (GFAP) and Iba1 antibodies. It was found that there was no
signiﬁcant difference in the extent of astrogliosis and microgliosis
between the random DNA sequence- and aptamer-treated mice (Figures 7F–7H), implying the mild brain neurodegeneration in the mice
at this time point.
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Taken together, these data showed that aptamers could reduce pathologic a-synuclein aggregation in vivo and ameliorated the motor
dysfunction in our PD mouse model.

DISCUSSION
Our study demonstrated the aptamers delivered by RVG-exosomes
reduced the pathological a-synuclein aggregates in vitro and in the
PD models, and ameliorated the mouse behavioral deﬁcits. The
aptamers loaded into the RVG-exosomes by transfection could be
preferentially targeted into neuronal cells and the mouse primary
neurons. In the primary neurons treated with a-synuclein PFF, the
aptamers were capable of retarding PFFs recruiting endogenous
a-synuclein into pathologic aggregates, consequently leading to
rescuing synaptic protein loss and mitigating neuron death caused
by pathologic a-synuclein. In the WT mice subjected to the intrastriatal injection of a-synuclein PFF, the aptamer treatment decreased the
pathological a-synuclein aggregates in the brain, particularly in the
cortex and midbrain, which are important areas affected by a-synuclein inclusions in PD (Figure 8). Taken together, our study highlighted the therapeutic potential of the RVG-exosome delivery of
aptamers to slow down or even halt a-synuclein pathological
conditions.
Accumulating studies suggest that during the PD development, the
misfolded a-synuclein proteins act as a seed, recruiting endogenous
a-synuclein into aggregates. Accumulation of a-synuclein aggregates
and subsequent amyloid chains results in generation of more seeds,
which cause accelerated accumulation of more pathological aggregates within cells and propagation between cells; consequently, the
process is hypothesized to be relevant to the PD development.
Thus, the aggregated a-synuclein might be worth targeting. It has
been demonstrated that Syn303, a species-independent monoclonal
antibody against the a-synuclein inclusions, can reduce pathological
a-synuclein aggregates in primary neurons.38,39 Likewise, this antibody also retarded the LB or LN pathology and improved motor impairments in the mouse a-synuclein PFF model, by targeting the
a-synuclein PFF and consequently limiting its recruitment of endogenous mouse a-synuclein into pathologic aggregates and blocking the
cell-to-cell transfer of a-synuclein aggregates.37 Given the inherent
weakness of the antibodies in clinical use, it is urgent to ﬁnd the antibody alternatives for application of the immunotherapy in PD. At
present it seems that aptamers are very appealing.20
In our recent work, by systematic evolution of ligands by exponential
enrichment (SELEX) on human recombinant a-synuclein, we obtained two aptamers (named as F5R1 and F5R2), which were found
to speciﬁcally target the human a-synuclein with high afﬁnities.24
In this study, we further found that these two aptamers could recognize the human and mouse PFF. Aptamer F5R1 still had a slight binding capacity with the mouse monomeric a-synuclein, whereas F5R2
absolutely did not cross-react with it. For directly blocking the a-synuclein PFF initial seeding effect without interfering with endogenous
a-synuclein in mice, aptamer F5R2 would be a good choice. Thus, the
aptamer F5R2 was chosen in our current study.
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The brain-speciﬁc targeted exosomes showed the potential to serve as
a highly efﬁcient strategy for transferring aptamers into the CNS.
Despite the recent advance in delivering nucleic acids, it is still challenging to target these cargos to speciﬁc tissues or cell types while
avoiding immunogenicity. It is particularly a real problem in the
case of chronic disease conditions, such as PD, that require a long
period of treatment. Exosomes are naturally occurring nano-sized
vesicles (30–120 nm) secreted by numerous cell types and have attracted much attention as drug delivery vehicles in recent years,
because exosomes may have an immune-privileged status that can
efﬁciently decrease drug clearance and show any toxicity.40,41 Further,
to confer the exosomes with the brain-targeting capability, the exosomal outer membrane protein, Lamp2b, was engineered to be fused
with the neuron-speciﬁc RVG peptide, leading to the RVG-modiﬁed
exosomes with the potential to deliver the nucleic acids into the cells
that express the neuronal nicotinic acetylcholine receptor.30,32 The
RVG-exosomes puriﬁed from HEK293T cells had been employed
to deliver siRNAs to downregulate opioid receptor Mu and inhibited
morphine relapse in mice.32 In this study, we constructed a plasmid
expressing the fusion protein of RVG-Lamp2b, and employed
HEK293T cells as donor cells to obtain the exosomes expressing
RVG on the membrane surface. The acquired RVG-exosomes showed
normal morphological characteristics after modiﬁcation, and the
DNA aptamer loading was conducted efﬁciently by transfection.
We demonstrated that these exosomes delivered aptamers into the
Neuro2A cells and primary neurons, further suggesting that we
have the right tool for the aptamer delivery to neurons.
LBs are the key pathological feature of PD and contain large amounts
of a-synuclein aggregates. It has been demonstrated that injection of
mouse a-synuclein PFF into non-transgenic (Tg) mice can recruit
endogenous a-synuclein to form LB or Lewy-like aggregates and
propagate this pathological feature in mice.37 Thus, in this study,
we selected the a-synuclein PFF mouse model to determine whether
aptamer-loaded RVG-exosomal therapy can impact on the level of
a-synuclein aggregates in vivo. As for the RVG-exosome administration route, normally an intravenous injection could yield rapid absorption and increase the therapeutic effect. However, in our study
we had to repeat the RVG-exosomes administration to the mice
many times. In this scenario, we considered that the intraperitoneal
injection was more preferable. Indeed, it was conﬁrmed that the aptamers could also be efﬁciently delivered into the brain by intraperitoneal injection, and this treatment with RVG-exosomes loaded with
aptamers did not induce signiﬁcant immune responses in vivo. As for
the aptamer therapeutic effect, consistent with our ﬁndings that aptamer F5R2 could inhibit the a-synuclein PFF-mediated a-synuclein
aggregation process in vitro, systemic administration of the aptamer
decreased the pathological a-synuclein aggregates in the cortex and
substantia nigra in the WT mice injected with mouse a-synuclein
PFF. Additionally, the aptamers also rescued the mouse-weakened
grip strength induced by the PFF under our experimental condition.
Notably, over the short experimental period, the mice did not demonstrate any obvious signs of the dopaminergic neuron loss,33 so it will
be of importance for the future studies to perform detailed clinical
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Figure 7. Aptamer Could Reduce PFF-Induced Aggregation of a-Synuclein In Vivo
(A) Immunohistochemistry for measuring the p-a-synuclein in the cortex. Mouse a-synuclein PFF injection led to a-synuclein aggregates in the ipsilateral and contralateral
prefrontal cortex, and the aptamer treatment significantly reduced the pathology in these regions. Scale bars, 75 mm. (B and C) Bar graph quantitation of the p-a-synuclein
level in the ipsilateral cortex (B) and contralateral cortex (C). For each treatment, the fluorescence intensity was measured with eight mice (three slides per mouse were
counted). The phosphorylated a-synuclein aggregates were expressed as fluorescence intensity, and the intensity in the aptamer-treated group was normalized to the group
treated with a random DNA sequence for statistical comparisons. Values are presented as mean ± SD. Student’s t test, ****p < 0.0001, compared with RVG-exosomes group
loaded with a random DNA sequence. (D) Confocal microscopy images to show the effect of aptamer F5R2 on the p-a-synuclein accumulation in the ipsilateral substantia
nigra. Anti-TH antibody was used to mark the TH-positive neurons (green). Scale bars, 75 mm. (E) Bar graph quantitation of the p-a-synuclein level in the ipsilateral substantia
nigra. For each treatment, the fluorescence intensity was measured similarly as in (B) with nine mice. Values are presented as mean ± SD. Student’s t test, ****p < 0.0001,
(legend continued on next page)
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In conclusion, by systemic administration of aptamers, we were able
to signiﬁcantly decrease the mouse pathological a-synuclein aggregates in the PD model. This is the ﬁrst time the aptamer was used
successfully in vivo to speciﬁcally reduce the level of a-synuclein
aggregates. These results bolstered the idea that this aptamer-RVGexosome system could be further developed to abrogate the disease
progression in PD, and they further shed light on the clinical treatment of many other CNS diseases, in particular neurodegenerative
disorders.

MATERIALS AND METHODS
Preparation of Recombinant a-Synuclein and PFF

The human and mouse a-synuclein genes were respectively subcloned
into pGEX-4T-1 vector, and they were expressed in Escherichia coli
BL21 (DE3) and puriﬁed as described previously.24 After the bacterial
endotoxins were removed using the Toxineraser endotoxin removal
kit (GeneScript, NJ, USA), the puriﬁed a-synuclein protein was
diluted in PBS to 5 mg/mL and shaken at 1,000 rpm under 37 C. Seven
days later, the protein was centrifuged at 100,000  g for 30 min at 4 C
to separate the a-synuclein ﬁbril (pellet fraction) from the a-synuclein
monomer (supernatant fraction). The a-synuclein ﬁbril was washed
once with PBS and resuspended in PBS to equal volume. The supernatant and pellet were resolved by SDS-PAGE and detected by Coomassie staining. Finally, the PFF and the a-synuclein monomer were
respectively aliquoted and stored at 80 C.
Figure 8. The Aptamers Exerted the Neuroprotective Effects by Retarding
PFFs Recruiting Endogenous a-Synuclein into Pathologic Aggregates
The a-synuclein PFF, once taken up by acceptor cells, may act as seeds for further
a-synuclein deposition within recipient cells, which triggers the stepwise progression of PD pathology. However, after the aptamers are delivered into the neuronal
cells by exosomes, they may block the PFFs recruiting endogenous a-synuclein into
pathologic aggregates, consequently preventing synaptic protein loss and mitigating neuron death.

evaluations of the aptamer treatment in mice with the prolonged
experimental period.
Although in this study it demonstrated the aptamers could inhibit the
intracellular pathological a-synuclein aggregation and could block
the Lewy pathology at the very beginning of PD status, the future
therapies should rely on early detection of PD by biomarkers such
as brain imaging or biological ﬂuid biomarkers currently under development for differential diagnosis.42 In this way, the aptamer-RVGexosomes system could be applied at an appropriate intervention
time for PD clinical treatment.

Preparation of Ab42 and Lysozyme Protein Assemblies

Ab42 oligomers and ﬁbrils were prepared as described previously.43
At ﬁrst, Ab42 (Abcam, Cambridge, UK) was dissolved to 1 mM in
100% hexaﬂuoroisopropanol (HFIP), and HFIP was subsequently
removed under vacuum. Then the peptide was resuspended in
DMSO to 5 mM. In order to generate oligomeric Ab42, we added
F-12 (without phenol red) culture media to bring the peptide to a ﬁnal
concentration of 100 mM, and the peptide was incubated at 4 C for
24 h. In order to generate ﬁbrillar Ab42, we added 10 mM HCl to
bring the peptide to a ﬁnal concentration of 100 mM, and the peptide
was incubated for 24 h at 37 C. Lysozyme ﬁbrils were prepared as
described previously.44 In brief, lysozyme (MP Biomedicals, Illkirch,
France) was dissolved to 10 mg/mL in 10 mM sodium phosphate
buffer (pH 7.0) and then incubated at 37 C for 7 days.
Dot Blotting

Proteins (BSA, human monomeric a-synuclein, human a-synuclein
PFF, mouse monomeric a-synuclein, mouse a-synuclein PFF; 1 mg
each) were respectively immobilized onto the nitrocellulose (NC)

compared with RVG-exosomes group loaded with a random DNA sequence. (F) The activation of microglia and astrocyte was analyzed by confocal microscopy after
aptamer treatment. The antibodies of anti-Iba1 and anti-GFAP were used to mark microglia (green) and astrocyte (red), respectively. Scale bars, 75 mm. (G) Bar graph
quantitation of Iba-1-positive cells. For each treatment, the number of Iba-1-positive cells was measured with nine mice (three slides per mouse were counted). The number in
the aptamer-treated group was normalized to the group treated with a random DNA sequence for statistical comparisons. Values are presented as mean ± SD. Student’s
t test: n.s., not significant, compared with RVG-exosomes group loaded with a random DNA sequence. (H) Occupied area analyses of GFAP-positive cells. For each
treatment, the area occupied by GFAP was measured with nine mice (three slides per mouse were counted). The area in the aptamer-treated group was normalized to the
group treated with a random DNA sequence for statistical comparisons. Values are presented as mean ± SD. Student’s t test: n.s., not significant, compared with the RVGexosomes group loaded with a random DNA sequence.
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membrane. After blocking with 5% milk in Tris-buffered saline
(50 mM Tris, 150 mM NaCl [pH 7.4]) with 0.2% (v/v) Tween-20
(TBST) for 1 h, the membrane was incubated with 100 nM ﬂuorescein
isothiocyanate (FITC)-labeled aptamer F5R1 or F5R2 for 2 h at room
temperature. Then the membrane was rinsed three times by TBST
and incubated with FITC antibody (1:20,000; Huayangzhenglong,
Sichuan, China) for 2 h. The membrane was rinsed three times by
TBST again and incubated with the rabbit IRDy680 secondary
antibody (1:10,000; LI-COR, Lincoln, NE, USA) for 1 h at room temperature. The dots were visualized with Odyssey Infrared Imaging
system (LI-COR, Lincoln, NE, USA). Subsequently, blots were stained
with Ponceau S (3-hydroxy-4-(2-sulfo-4-[4-sulfophenylazo]phenylazo)-2,7-naphthalenedisulfonic acid; PPLYGEN, Beijing, China) to
conﬁrm protein retention.

West Chester, PA, USA). Two minutes later, the grids were negatively
stained with 2% uranyl acetate solution for 5 min at room temperature. Then the grids were rinsed three times with double-distilled
H2O and viewed by a JEM electron microscope (Tokyo, Japan). For
biochemical assay, exosomes were lysed in Laemmli buffer, then
loaded on a 6%–10% (w/v) SDS-PAGE gel. The proteins were transferred from the gel to polyvinylidene ﬂuoride (PVDF) membranes
and blocked with 5% milk. The membranes were incubated with
Alix antibody (1:1,000; Abcam, Cambridge, UK) for 2 h at room temperature. After rinsing three times with TBST, the membranes were
incubated with the rabbit IRDy680 secondary antibody (1:10,000;
LI-COR, Lincoln, NE, USA) for 1 h at room temperature. The bands
were visualized using the Odyssey Infrared Imaging system (LI-COR,
Lincoln, NE, USA).

ThT Fluorescence Assay of a-Synuclein Fibril Formation In Vitro

Exosomal Staining

a-Synuclein was dissolved to a concentration of 20 mM in the assembly buffer (50 mM Tris and 150 mM NaCl [pH 7.5]) either alone or
with 10% PFF. The mixture was incubated with the aptamer at a 1:1
ratio of PFF at 37 C with constant agitation (1,000 rpm). The samples
were collected at the indicated time point, and the rate of ﬁbrillogenesis was monitored by the ThT (20 mM) ﬂuorescence assay (excitation
at 450 nm and emission at 480 nm) using a Microplate reader (PerkinElmer, Waltham, MA, USA).

Exosomes were stained with CellVue claret far-red ﬂuorescent cell
linker kits (Sigma, St. Louis, MO, USA) according to the manufacturer’s protocol. In brief, the exosomes were resuspended in the labeling vehicle provided with the kit (Diluent C) to a ﬁnal concentration of
1 mg/mL. Then the exosomes were rapidly added to 2xDye solution
and immediately mixed by pipetting to stain the exosomal membrane.
After 5-min incubation at room temperature, the staining was stopped
by adding an equal volume of 1% BSA, and the excess dye was
removed by ultracentrifuge at 100,000  g for 90 min at 4 C. The exosomes were washed once with PBS and then resuspended in 200 mL of
PBS for monitoring the uptake efﬁciency in cells. The ﬂuorescence intensity of CellVue claret-labeled exosomes was detected by confocal
microscope using 655 nm excitation and 675 nm emission.

Cell Culture, RVG-Modified Exosomes Isolation, and Aptamer
Loading

The human embryonic kidney cell line (HEK293T) and mouse
myoblast C2C12cell line were cultured in DMEM with 10% (v/v) fetal
bovine serum (FBS), 50 U/mL penicillin, and 50 mg/mL streptomycin. A fast-growing mouse neuroblastoma Neuro2A cell line was
cultured in Ham’s F-12 Nutrient Mixture (F12) with 10% (v/v)
FBS, 50 U/mL penicillin, and 50 mg/mL streptomycin. All of the cells
were incubated in a 5% CO2 atmosphere at 37 C.

Primary Neuron Culture and a-Synuclein PFF Treatment

The RVG coding sequence was fused to the N terminus of the mouse
Lamp2b (as illustrated in Figure S3A). Then, the RVG-Lamp2b (or
myc-RVG-lamp2b) plasmids were transfected into HEK293T cells
by PEI (Polysciences), and the cells were cultured in exosomesfree DMEM. After 2 days, the medium was collected and RVG-modiﬁed exosomes were puriﬁed by gradient centrifugation.32 For aptamer
loading, the aptamers (200 pmol) were incubated with PEI (1 mg/mL)
in PBS for 30 min; then 10 mg of exosomes was added to the mixture
and incubated for the indicated time at 37 C. The excess aptamers
and residual PEI were removed by ultracentrifuge at 100,000  g
for 90 min at 4 C. The pellet was washed and then resuspended in
PBS. For loading efﬁciency analysis, the ﬂuorescence intensity of
Alexa 594 was measured before and after loading aptamer into exosomes by microplate reader (PerkinElmer, Waltham, MA, USA) using 590 nm excitation and 617 nm emission.

Primary cortex neurons were prepared from C57BL/6J mouse embryos
(days 14–16).24 All experiments were authorized by the Institutional
Animal Care and Use Committee of the Capital Medical University
(approval No. AEEI-2016-057) and performed according to the NIH
Guide for the Care and Use of Laboratory Animals. In brief, the dissociated neurons were plated onto the poly-L-lysine (Sigma, St. Louis, MO,
USA)-coated coverslips or dishes at 20,000–40,000 or 70,000–100,000
cells/cm2, respectively. The cells were cultured in Neurobasal medium
(GIBCO, VA, USA) supplemented with L-glutamine (0.5 mM) and
50 B27 supplement (for a ﬁnal concentration of 1; GIBCO). Because
a-synuclein is expressed only at mature synapses, exosome and PFF
treatment were performed on neurons at 7 days in vitro (DIV). As for
the aptamer-loaded RVG-exosomes treatment, 6 mg of the exosomes
per 106 neurons was used. As for the PFF treatment, the PFF was ﬁrst
diluted in PBS to a ﬁnal concentration of 0.1 mg/mL and sonicated
with 60 pulses. For immunoﬂuorescence experiment, PFF at a ﬁnal
concentration of 1 mg/mL was used. For the immunoblotting experiment, PFF at a ﬁnal concentration of 4 mg/mL was used. At 21 DIV,
the neurons were harvested further to be analyzed.

Characterization of the RVG-Exosomes

Immunofluorescence

For TEM assay, exosomes (10 mL) were placed on 400-mesh copper
grids covered by carbon-stabilized Formvar ﬁlm (SP I Supplies,

Neurons or cells were ﬁxed with 4% (w/v) paraformaldehyde and 4%
(w/v) sucrose in PBS for 15 min. To extract soluble proteins, we added
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1% (v/v) TX-100 to the ﬁx buffer. The cells were rinsed ﬁve times with
PBS and then permeabilized and blocked with 3% (w/v) BSA/0.1%
(v/v) TX-100 for 15 min. Then the cells were incubated with the primary antibody [anti-a-synuclein (1:500; BD Biosciences, Franklin
Lakes, NJ, USA) or anti-p-a-synuclein (1:400; Abcam, Cambridge,
UK)] for 2 h at room temperature. After rinsing ﬁve times with
PBS, the cells were incubated with a secondary antibody, mouse
IRDy594, rabbit IRDy488, or rabbit IRDy647 (1:500; LI-COR,
Lincoln, NE, USA), for 1 h at room temperature. The ﬂuorescence
was visualized with confocal microscope (Leica Microsystems, Tokyo,
Japan).
Western Blotting

The primary neurons were resuspended in 1% (v/v) TX-100/TBS
with protease and phosphatase inhibitors and then sonicated 10 times
at a 0.5-s pulse and incubated on ice for 30 min. The cell lysates were
centrifuged (100,000  g) at 4 C for 30 min, and the supernatant was
harvested as a TX-soluble fraction. The pellets were washed with 1%
(v/v) TX-100/TBS followed by centrifugation at 100,000  g at 4 C,
and the TX-insoluble proteins were extracted with 2% (w/v) SDS/
TBS and ﬁnally reconstituted in SDS/TBS buffer with equal volume.
The protein concentrations of the TX-soluble fraction and the TXinsoluble fraction were determined using a bicinchoninic acid protein
assay kit (Pierce Biotechnology, Rockford, IL, USA). The proteins
were resolved by the 6%–15% SDS-PAGE gel and transferred to a
PVDF membrane, which was blocked with 5% milk. The membranes
were incubated with anti-a-synuclein (1:2,000; BD Biosciences,
Franklin Lakes, NJ, USA), anti-b-actin (1:5,000; Beijing GuanXingYu,
Beijing, China), anti-p-a-synuclein (1:1,000; Abcam, Cambridge,
UK), anti-SNAP25 (1:1,000; ABclonal, Wuhan, China), or anti-synapsin II (homemade, 1:1,000) antibodies for 2 h at room temperature.
After rinsing three times with TBST, the membranes were incubated
with the secondary antibody, mouse IRDy680 or rabbit IRDy680
(1:10,000; LI-COR, Lincoln, NE, USA), for 1 h at room temperature.
The bands were detected with the Odyssey Infrared Imaging system
(LI-COR, Lincoln, NE, USA).
Measurement of Cell Viability

Cell viability was determined with the MTT assay. MTT (Promega,
Madison, WI, USA) was used at a ﬁnal concentration of 0.5 mg/mL
and incubated with cells for 4 h. After washing two times with PBS,
formazan crystals were dissolved in 100 mL DMSO. Absorbance
was read at 490 nm with a microplate reader (PerkinElmer, Waltham,
MA, USA). The cytotoxicity was measured by the LDH assay, which
was carried out using a cytotoxicity detection kit (Roche Diagnostics,
Mannheim, Germany). LDH release was measured in a 100-mL
aliquot of supernatant, with 100 mL preservation solution used as a
blank to correct the optical density reading at 490 nm.
Delivery of Exosomal DNA Aptamer into the Mouse Brain

Two- to three-month-old C57BL/6J female mice were used for experiments. The animals were obtained from Vital River Laboratories
(Beijing, China), and all experiments were authorized by the Institutional Animal Care and Use Committee of the Capital Medical Uni-
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versity (approval No. AEEI-2016-057) and performed according to
the NIH Guide for the Care and Use of Laboratory Animals. All animal
experiments were designed to minimize the suffering and pain of the
animals.
Aptamer-loaded RVG-exosomes (120 mg exosomes per mouse) were
administered to the mice by intraperitoneal injection, with random
DNA sequence as control. After 24 h, the mice were intrastriatally
injected with mouse a-synuclein PFF, which was diluted in sterile
PBS to a ﬁnal concentration of 2.5 mg/mL with brief sonication. In
brief, the mice were deeply anesthetized with ketamine (100 mg/kg;
Bela-Pharm) and xylazine (10 mg/kg; Bela-Pharm), then were
stereotaxically injected with PFF (5 mg) by inserting a single needle
into the right dorsal neostriatum (coordinates: +0.2 mm relative to
bregma, +2.0 mm from midline, +2.6 mm beneath the dura). Injections were performed using a 10-mL syringe at a rate of 0.1 mL per
min (2 mL total per site) with the needle in place for >5 min after injection for a complete absorption of the solution. Sterile PBS was used
as negative control; then aptamer-loaded RVG-exosomes were
administered to animals weekly by intraperitoneal injection until sacriﬁce at predetermined period.
Immunohistochemistry

Mice were anesthetized and perfused with physiological saline followed by 4% paraformaldehyde/PBS, and the brains was removed,
followed by ﬁxation in 4% paraformaldehyde overnight and transfer
to 30% sucrose for cryoprotection. Then the brains were sectioned at a
thickness of 40 mm, and the sections were incubated in 0.3% TX-100/
PBS for 60 min and then incubated in 3% H2O2 for 10 min to block
endogenous peroxidase activity. After washing in PBS, sections were
incubated in 10% goat serum followed by 0.1% TX-100 in PBS for
60 min, then incubated in anti-tyrosine hydroxylase (TH) (1:8,000;
Sigma, St. Louis, MO, USA), anti-p-a-synuclein (1:400; Abcam, Cambridge, UK), anti-MAP2 (1:400; Abcam, Cambridge, UK), anti-GFAP
(1:400; Abcam, Cambridge, UK), or anti-Iba1 (1:200; Wako Pure
Chemical Industries, Japan) antibodies for 2 h at room temperature.
After washing in PBS, the brain slices were incubated with secondary
antibody, mouse IRDy594 or rabbit IRDy488 (1:500; LI-COR,
Lincoln, NE, USA), for 1 h at room temperature. The ﬂuorescence
was visualized and analyzed with confocal microscope (Leica Microsystems, Tokyo, Japan).
Behavioral Analysis

Behavioral experiments were conducted 30 days post PFF injection.
Mice were habituated to the testing room 1 h before tests, and the
apparatuses were cleaned with 70% ethanol in between animals to
minimize odor cues. For rotarod test, each mouse was given a training
session (four 5-min trials, 5 min apart) to acclimate them to the rotarod apparatus. During the test period, each mouse was placed on
the rotarod with increasing speed, from 4 to 40 rpm in 300 s. The latency to fall off the rotarod within this time period was recorded. Each
mouse received two consecutive trials, and the mean latency to fall in
each group was used in the analysis. For the wire hang test, it was conducted with a modiﬁed protocol previously described.45 The mice
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were placed on the top of a standard wire cage lid. The lid was lightly
shaken to cause the animals to grip the wires and then turned upside
down. The latency of mice to fall off the wire grid was measured, and
average values were computed from two trials (15 min apart). Trials
were stopped if the mouse remained on the lid after 15 min. For each
group, we used 12 female mice for behavioral analysis.
Statistical Analysis

The statistical analysis was completed using GraphPad Prism software (version 6; GraphPad, La Jolla, CA, USA). Data results are presented as mean ± SD with at least three independent experiments.
Differences between two means and among multiple means were assessed by unpaired two-tailed Student’s t test or ANOVA followed by
Tukey’s post hoc test, respectively. Assessments with p < 0.05 were
considered statistically signiﬁcant.
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